Cargando…

281. Cefdinir Prescribing Increased in Low-Income Children in Kentucky From 2012 to 2016

BACKGROUND: Cefdinir is frequently prescribed to pediatric outpatients with respiratory infections despite a lack of first-line indications. The use of cefdinir should be limited given its poor efficacy against Streptococcus pneumoniae, suboptimal pharmacokinetic and pharmacodynamic parameters, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Michael, Vidwan, Navjyot, Wattles, Bethany, Ghosal, Soutik, Feygin, Yana, Creel, Liza, Myers, John, Woods, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253407/
http://dx.doi.org/10.1093/ofid/ofy210.292
_version_ 1783373487079948288
author Smith, Michael
Vidwan, Navjyot
Wattles, Bethany
Ghosal, Soutik
Feygin, Yana
Creel, Liza
Myers, John
Woods, Charles
author_facet Smith, Michael
Vidwan, Navjyot
Wattles, Bethany
Ghosal, Soutik
Feygin, Yana
Creel, Liza
Myers, John
Woods, Charles
author_sort Smith, Michael
collection PubMed
description BACKGROUND: Cefdinir is frequently prescribed to pediatric outpatients with respiratory infections despite a lack of first-line indications. The use of cefdinir should be limited given its poor efficacy against Streptococcus pneumoniae, suboptimal pharmacokinetic and pharmacodynamic parameters, and high cost. We describe cefdinir use over time in the pediatric Kentucky (KY) Medicaid population including rates of use, associated diagnoses, and cost to the Medicaid system. METHODS: We reviewed KY Medicaid pharmacy and medical claims from 2012 to 2016 for all patients <20 years of age. Cefdinir prescriptions were identified by national drug codes and linked to medical claims within 3 days prior to the prescription date. Diagnoses were classified into the following groups by ICD9 and ICD10 codes: acute otitis media (AOM), sinusitis, pharyngitis, lower respiratory infections, and urinary tract infections. Upper respiratory infections (URIs) commonly caused by viruses (e.g., nasopharyngitis, bronchitis, cough) were categorized as presumed viral infections. Cost data were extracted from pharmacy claims. Cochran-Armitage was used to test for trends across the study period. RESULTS: Cefdinir prescriptions significantly increased from 60,334 (8% of all antibiotic prescriptions) in 2012 to 99,053 (13% of all antibiotic prescriptions) in 2016 (P < 0.001). Cefdinir use in rate per 1,000 children increased from 195 in 2012 to 294 in 2016. Medicaid spending on cefdinir increased from $2.3M (15% of all antibiotic spending) in 2012 to $4.7M (27% of all spending) in 2016. Eighty-eight percent of pharmacy claims for cefdinir had an associated medical claim within 3 days prior to prescription. Indications associated with cefdinir are summarized in Figure 1. Three groups accounted for the majority of cefdinir use: AOM, presumed viral infections, and pharyngitis. CONCLUSION: Outpatient cefdinir use in pediatric patients served by KY Medicaid significantly increased over the study period. Much of this use was inappropriate. Antibiotics are not useful against viral infections, which accounted for 23% of cefdiniruse. When antibiotics are indicated for bacterial URI, agents with better pneumococcal coverage are preferred. Preventing overuse of this costly, broad-spectrum antibiotic is an important focus for antimicrobial stewardship efforts. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253407
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62534072018-11-28 281. Cefdinir Prescribing Increased in Low-Income Children in Kentucky From 2012 to 2016 Smith, Michael Vidwan, Navjyot Wattles, Bethany Ghosal, Soutik Feygin, Yana Creel, Liza Myers, John Woods, Charles Open Forum Infect Dis Abstracts BACKGROUND: Cefdinir is frequently prescribed to pediatric outpatients with respiratory infections despite a lack of first-line indications. The use of cefdinir should be limited given its poor efficacy against Streptococcus pneumoniae, suboptimal pharmacokinetic and pharmacodynamic parameters, and high cost. We describe cefdinir use over time in the pediatric Kentucky (KY) Medicaid population including rates of use, associated diagnoses, and cost to the Medicaid system. METHODS: We reviewed KY Medicaid pharmacy and medical claims from 2012 to 2016 for all patients <20 years of age. Cefdinir prescriptions were identified by national drug codes and linked to medical claims within 3 days prior to the prescription date. Diagnoses were classified into the following groups by ICD9 and ICD10 codes: acute otitis media (AOM), sinusitis, pharyngitis, lower respiratory infections, and urinary tract infections. Upper respiratory infections (URIs) commonly caused by viruses (e.g., nasopharyngitis, bronchitis, cough) were categorized as presumed viral infections. Cost data were extracted from pharmacy claims. Cochran-Armitage was used to test for trends across the study period. RESULTS: Cefdinir prescriptions significantly increased from 60,334 (8% of all antibiotic prescriptions) in 2012 to 99,053 (13% of all antibiotic prescriptions) in 2016 (P < 0.001). Cefdinir use in rate per 1,000 children increased from 195 in 2012 to 294 in 2016. Medicaid spending on cefdinir increased from $2.3M (15% of all antibiotic spending) in 2012 to $4.7M (27% of all spending) in 2016. Eighty-eight percent of pharmacy claims for cefdinir had an associated medical claim within 3 days prior to prescription. Indications associated with cefdinir are summarized in Figure 1. Three groups accounted for the majority of cefdinir use: AOM, presumed viral infections, and pharyngitis. CONCLUSION: Outpatient cefdinir use in pediatric patients served by KY Medicaid significantly increased over the study period. Much of this use was inappropriate. Antibiotics are not useful against viral infections, which accounted for 23% of cefdiniruse. When antibiotics are indicated for bacterial URI, agents with better pneumococcal coverage are preferred. Preventing overuse of this costly, broad-spectrum antibiotic is an important focus for antimicrobial stewardship efforts. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253407/ http://dx.doi.org/10.1093/ofid/ofy210.292 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Smith, Michael
Vidwan, Navjyot
Wattles, Bethany
Ghosal, Soutik
Feygin, Yana
Creel, Liza
Myers, John
Woods, Charles
281. Cefdinir Prescribing Increased in Low-Income Children in Kentucky From 2012 to 2016
title 281. Cefdinir Prescribing Increased in Low-Income Children in Kentucky From 2012 to 2016
title_full 281. Cefdinir Prescribing Increased in Low-Income Children in Kentucky From 2012 to 2016
title_fullStr 281. Cefdinir Prescribing Increased in Low-Income Children in Kentucky From 2012 to 2016
title_full_unstemmed 281. Cefdinir Prescribing Increased in Low-Income Children in Kentucky From 2012 to 2016
title_short 281. Cefdinir Prescribing Increased in Low-Income Children in Kentucky From 2012 to 2016
title_sort 281. cefdinir prescribing increased in low-income children in kentucky from 2012 to 2016
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253407/
http://dx.doi.org/10.1093/ofid/ofy210.292
work_keys_str_mv AT smithmichael 281cefdinirprescribingincreasedinlowincomechildreninkentuckyfrom2012to2016
AT vidwannavjyot 281cefdinirprescribingincreasedinlowincomechildreninkentuckyfrom2012to2016
AT wattlesbethany 281cefdinirprescribingincreasedinlowincomechildreninkentuckyfrom2012to2016
AT ghosalsoutik 281cefdinirprescribingincreasedinlowincomechildreninkentuckyfrom2012to2016
AT feyginyana 281cefdinirprescribingincreasedinlowincomechildreninkentuckyfrom2012to2016
AT creelliza 281cefdinirprescribingincreasedinlowincomechildreninkentuckyfrom2012to2016
AT myersjohn 281cefdinirprescribingincreasedinlowincomechildreninkentuckyfrom2012to2016
AT woodscharles 281cefdinirprescribingincreasedinlowincomechildreninkentuckyfrom2012to2016